Key result
Metabolic syndrome is linked to ~41% higher all-cause mortality, with hypertension further increasing CV death.
Why the study?
It is unclear how different phenotypes of metabolic syndrome affect all-cause and cardiovascular mortality rates among the Iranian population.
Cohort (n=6,323)
Yes
Should not yet change practice in metabolic syndrome; extends observational evidence on hypertension phenotypes and mortality risk.
BACKGROUND: This study aimed to focus on different phenotypes of metabolic syndrome (MetS) and their impact on the cardiovascular disease (CVD) events among a sample of the Iranian population. MATERIALS AND METHODS: The Isfahan cohort study is a population-based, on-going longitudinal study of adults aged 35 years old or more, living in urban and rural areas of three counties in central Iran namely Isfahan, Najafabad and Arak. Participants were selected by multistage random sampling and were recruited to reflect the age, sex and urban/rural distribution of the community. The sample was restricted to subjects with MetS based on the National Cholesterol Education Program Adult Treatment Panel III criteria and no history of coronary heart disease, stroke, or cancer at the time of the baseline clinical examination. RESULTS: Among different phenotypes of MetS components, clustering of high triglycerides (TGs), low high-density lipoprotein (HDL) and abdominal obesity (ABO) was the most related to the all-cause mortality among women and followed in order by high TGs, hypertension (HTN) and ABO. In men, the highest rate of all-cause mortality was related to high TGs, low HDL, and HTN. Clustering of four components (high TGs, low HDL and HTN and obesity) is the most related to all-cause mortality in the both sexes (12.1% in men, and 21.5% in women). CONCLUSION: This study showed different phenotypes of MetS related with all-cause mortality rate and existing HTN in the phenotype of MetS increased the incidence of CVD mortality.
No takes yet. Share an insight, caveat, or question.
Khosravi et al. (2016) conducted a cohort in Metabolic syndrome (n=6,323). Metabolic syndrome vs. Without metabolic syndrome was evaluated on All-cause mortality (HR 1.41, 95% CI 1.16-1.72, p=≥0.001). Metabolic syndrome was significantly associated with an increased risk of all-cause mortality (HR 1.41), and the presence of hypertension within metabolic syndrome phenotypes increased the incidence of cardiovascular mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: